It could include rare diseases, but it is to take drugs that have gone very often through the phase I, which is the safety in patients, and so we know they are safe in patients, and yet, as you say, they were shown in phase II not to be effective for the indication for which it was tested.
Cela pourrait comprendre les maladies rares, mais il s'agit de prendre des médicaments qui ont souvent franchi la phase I, celle de l'innocuité chez les patients, et dont nous savons qu'ils sont sans danger pour les patients, et qui pourtant, comme vous le dites, sont jugés inefficaces à la phase II pour le trouble visé.